Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 11/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208926 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL1926641 | 0.85 | KDM4E (0.37) | LMNACYP3A4HIF1AADRB2APP | |
| SCHEMBL1210556 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL1207874 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL1927417 | 0.84 | PPARA (0.40) | APPPPARGPPARAPPARD | |
| Hydrochloric Acid SCHEMBL3747460 | 0.84 | ADRB2 (0.44) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL1210698 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL1209512 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNACYP3A4HIF1AADRB2 | |
| SCHEMBL9544068 | 0.77 | PPARA (0.46) | ALDH1A1LMNAAPPPPARGPPARA | |
| SCHEMBL9544071 | 0.77 | PPARA (0.46) | ALDH1A1LMNAAPPPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7829592-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, PARK7, DDT | ALDH1A1 636/4885LMNA 3425/4885CYP3A4 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.